Xencor to Present at Wedbush Securities 2014 Life Sciences Management Access Conference
MONROVIA, Calif., Aug. 5, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that John Desjarlais, Ph.D., senior vice president, research and chief scientific officer, will present at the Wedbush Securities 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014 at 3:40 p.m. EDT in New York City, NY.
A live audio webcast of the presentation will be available on the "Events and Presentations" section in the Investors section of the company's website located at http://investors.xencor.com/events.cfm. A replay of the presentation will be posted on the Xencor website approximately one hour after the event and will be available for 30 days following the presentation.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, seven candidates are in clinical development internally and with partners that have been engineered with Xencor's XmAb® technology. Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in Phase 1 development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion and Boehringer Ingelheim.
For more information, please visit www.xencor.com.
SOURCE Xencor, Inc.